This deepened partnership and agreement with IBA Dosimetry will not only reinforce ScandiDos´ position on the market but will also provide ScandiDos with an expected increase in sales of its flagship product Delta4 Phantom+. The intensification of the cooperation between the two companies will enable IBA to offer a new value-added solution to its customers. The partnership will benefit both radiation therapy clinics and cancer patients worldwide.
 
”We are thrilled to deepen our partnership with IBA Dosimetry, a company that shares our passion for advancing patient QA solutions” says Gustaf Piehl, CEO of ScandiDos. “The agreement with IBA is an important milestone for ScandiDos and underscores the value of our patient QA solutions in the industry.”
 
The new sales and interoperability agreement between ScandiDos and IBA Dosimetry enables IBA to offer its customers a streamlined patient view where 3D measurements from the Delta4 Phantom+ can be displayed in the IBA myQA iON software. This feature gives IBA users a simple overview of the various calculations and measurements from both the Delta4 Phantom+ and IBA myQA iON software, saving time and improving accuracy.